Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

HARNESSING HETEROTYPIC T CELL CLUSTERS TO BOOST TIL CANCER THERAPY

Objective

Despite major advances in cancer immunotherapy, most patients still lack durable benefit. Tumor-infiltrating T lymphocyte (TIL) therapy can induce deep cancer remissions, but potency varies and complete clinical responses are limited to 20%. Crucially, although truly tumor-reactive T cells are rare in cancers (<5%), current manufacturing protocols expand TILs in bulk, without inclusion of a selection or enrichment step. Together, these observations create both a dire clinical need and unique opportunity to augment the impact of this type of immunotherapy, namely by selecting the actively tumor-killing T cells.
In our current ERC Advanced project ReverT, we discovered that tumor-killing T cells are strongly enriched in so-called heterotypic cell clusters: tight conjugates of T cells with tumor (melanoma) cells and/or antigen-presenting cells. We developed an isolation procedure to capture intact clusters straight from clinical cancer specimens from patients. These T cell clusters can be effectively expanded and exhibit a 9-fold increase in tumor-killing activity against patient tumors.
This ERC PoC project translates our findings into a “CLUSTER-TIL” manufacturing module, integrating upstream of the standard production pipeline to enable enhanced TIL therapy. We will develop and optimize a scalable procedure to purify cluster-derived T cells from tumor digests from patients, define quality metrics for tumor reactivity and benchmark to the standard bulk TIL workflow. CLUSTER-TIL will deliver a highly potent, consistent anti-cancer T cell therapy that will be tested in a planned investigator-initiated Phase 2a trial in melanoma. We observe similar clusters in other solid tumor types, enabling expansion to patient groups beyond melanoma. Furthermore, two patent applications protect the CLUSTER-TIL technology. This PoC will also generate follow-on IP to support a spin-off applying the technology for broader clinical implementation and improved patient outcomes.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) ERC-2026-POC

See all projects funded under this call

Host institution

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 150 000,00
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Beneficiaries (1)

My booklet 0 0